OGEN

Oragenics

• NASDAQ·07/08 06:34

  Oragenics Activates Third Site For Phase 2a Of ONP-002 In Treating Concussions, Data By Q4 '26

• TipRanks·07/06 20:36

  Oragenics Appoints New Chief Financial Officer and Leader

• TipRanks·05/19 12:58

  Oragenics Highlights Investor Outreach at Micro-Cap Conference

• Seeking Alpha·05/18 16:19

  Oragenics reports Q1 results

• Benzinga·05/08 22:14

  Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY

• Benzinga·05/07 12:34

  Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics

• NASDAQ·04/21 02:41

  Oragenics Advances Phase IIa Trial Of ONP-002 For Concussion

• TipRanks·04/20 14:01

  Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

• Benzinga·04/20 13:04

  Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury

• NASDAQ·04/14 08:51

  Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002

• TipRanks·04/13 15:38

  Oragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia

• Benzinga·04/13 12:34

  Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002

• TipRanks·03/31 23:45

  Oragenics Sets New 2025 Annual Shareholder Meeting Date

• TipRanks·03/17 12:49

  Oragenics files annual report on Form 10-K

• NASDAQ·03/12 14:30

  Oragenics Kick Off Phase IIa Trial Operations For ONP-002; Stock Up